Despite the different effects on the proliferation of different CRC cells, CBX3 KO significantly increased or tended to increase the chemosensitivity of both HT29 and SW480 cells to Irinotecan and Fluorouracil (5-FU), two of the first-line chemotherapy drugs in CRC treatment (Fig. 9C,D). This evidence concerns the gene CBX3 and colorectal carcinoma.